Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease. A review

Journal of Crohn's and Colitis

Volumn 8, Issue 3, 2014, Pages 183-190

  Linares, Pablo M ^a,b   Chaparro, María ^a,b   Gisbert, Javier P ^a,b  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Angiogenesis; Angiopoietins; Crohn's disease; Growth factors; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ANGIOGENESIS; ANGIOPOIETINS; CROHN'S DISEASE; GROWTH FACTORS; INFLAMMATORY BOWEL DISEASE; ULCERATIVE COLITIS;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; RECEPTOR, TIE-2;

EID: 84894254453     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.06.013     Document Type: Review

References (90)

1. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989, 170:2-6. [discussion 16-9].
2. Satsangi J., Morecroft J., Shah N.B., Nimmo E. Genetics of inflammatory bowel disease: scientific and clinical implications. Best Pract Res Clin Gastroenterol 2003, 17:3-18.
3. Sands B.E. Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007, 42:16-25.
4. Shantha Kumara H.M., Grieco M.J., Yan X., Kalady M.F., DiMaggio V., Kim D.G., et al. Minimally invasive colorectal resection for cancer is associated with a short-lived decrease in soluble Tie-2 receptor levels, which may transiently inhibit VEGF-mediated angiogenesis (via altered blood levels of free Ang-1 and Ang-2). Surg Endosc 2010, 24:2581-2587.
5. Ganta V.C., Cromer W., Mills G.L., Traylor J., Jennings M., Daley S., et al. Angiopoietin-2 in experimental colitis. Inflamm Bowel Dis 2009, 16:1029-1039.
6. Pousa I.D., Mate J., Gisbert J.P. Angiogenesis in inflammatory bowel disease. Eur J Clin Invest 2008, 38:73-81.
7. Felmeden D.C., Blann A.D., Lip G.Y. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J 2003, 24:586-603.
8. Jerkic M., Peter M., Ardelean D., Fine M., Konerding M.A., Letarte M. Dextran sulfate sodium leads to chronic colitis and pathological angiogenesis in Endoglin heterozygous mice. Inflamm Bowel Dis 2010, 16:1859-1870.
9. Jackson J.R., Seed M.P., Kircher C.H., Willoughby D.A., Winkler J.D. The codependence of angiogenesis and chronic inflammation. FASEB J 1997, 11:457-465.
10. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039.
11. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003, 3:643-651.
12. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
13. Dachs G.U., Tozer G.M. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000, 36:1649-1660.
14. Giatromanolaki A., Sivridis E., Maltezos E., Papazoglou D., Simopoulos C., Gatter K.C., et al. Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol 2003, 56:209-213.
15. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9:653-660.
16. Autiero M., Luttun A., Tjwa M., Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003, 1:1356-1370.
17. Goebel S., Huang M., Davis W.C., Jennings M., Siahaan T.J., Alexander J.S., et al. VEGF-A stimulation of leukocyte adhesion to colonic microvascular endothelium: implications for inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2006, 290:G648-G654.
18. Chidlow J.H., Langston W., Greer J.J., Ostanin D., Abdelbaqi M., Houghton J., et al. Differential angiogenic regulation of experimental colitis. Am J Pathol 2006, 169:2014-2030.
19. Hatoum O.A., Heidemann J., Binion D.G. The intestinal microvasculature as a therapeutic target in inflammatory bowel disease. Ann N Y Acad Sci 2006, 1072:78-97.
20. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
21. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
22. Eklund L., Olsen B.R. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 2006, 312:630-641.
23. Fiedler U., Krissl T., Koidl S., Weiss C., Koblizek T., Deutsch U., et al. Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem 2003, 278:1721-1727.
24. Wong A.L., Haroon Z.A., Werner S., Dewhirst M.W., Greenberg C.S., Peters K.G. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 1997, 81:567-574.
25. Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton D.L., Jain V., et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87:1161-1169.
26. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
27. Brindle N.P., Saharinen P., Alitalo K. Signaling and functions of angiopoietin-1 in vascular protection. Circ Res 2006, 98:1014-1023.
28. Fam N.P., Verma S., Kutryk M., Stewart D.J. Clinician guide to angiogenesis. Circulation 2003, 108:2613-2618.
29. Gale N.W., Thurston G., Hackett S.F., Renard R., Wang Q., McClain J., et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 2002, 3:411-423.
30. Augustin H.G., Koh G.Y., Thurston G., Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009, 10:165-177.
31. Suri C., Jones P.F., Patan S., Bartunkova S., Maisonpierre P.C., Davis S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996, 87:1171-1180.
32. Thurston G., Suri C., Smith K., McClain J., Sato T.N., Yancopoulos G.D., et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999, 286:2511-2514.
33. Lee H.J., Cho C.H., Hwang S.J., Choi H.H., Kim K.T., Ahn S.Y., et al. Biological characterization of angiopoietin-3 and angiopoietin-4. FASEB J 2004, 18:1200-1208.
34. Tsigkos S., Koutsilieris M., Papapetropoulos A. Angiopoietins in angiogenesis and beyond. Expert Opin Investig Drugs 2003, 12:933-941.
35. Sundberg C., Kowanetz M., Brown L.F., Detmar M., Dvorak H.F. Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab Invest 2002, 82:387-401.
36. London N.R., Whitehead K.J., Li D.Y. Endogenous endothelial cell signaling systems maintain vascular stability. Angiogenesis 2009, 12:149-158.
37. Fiedler U., Augustin H.G. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006, 27:552-558.
38. Kim I., Kim J.H., Moon S.O., Kwak H.J., Kim N.G., Koh G.Y. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Oncogene 2000, 19:4549-4552.
39. Lobov I.B., Brooks P.C., Lang R.A. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 2002, 99:11205-11210.
40. Oshima Y., Oshima S., Nambu H., Kachi S., Takahashi K., Umeda N., et al. Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive. FASEB J 2005, 19:963-965.
41. Roviezzo F., Tsigkos S., Kotanidou A., Bucci M., Brancaleone V., Cirino G., et al. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther 2005, 314:738-744.
42. Scharpfenecker M., Fiedler U., Reiss Y., Augustin H.G. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005, 118:771-780.
43. Simoes D.C., Vassilakopoulos T., Toumpanakis D., Petrochilou K., Roussos C., Papapetropoulos A. Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma. Am J Respir Crit Care Med 2008, 177:1314-1321.
44. Lee K.S., Lee K.Y., Kim S.R., Park H.S., Park S.J., Min K.H., et al. Blockade of airway inflammation and hyper-responsiveness by an angiopoietin-1 variant, COMP-Ang1. Exp Mol Med 2007, 39:733-745.
45. Pizurki L., Zhou Z., Glynos K., Roussos C., Papapetropoulos A. Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. Br J Pharmacol 2003, 139:329-336.
46. Kim I., Moon S.O., Park S.K., Chae S.W., Koh G.Y. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 2001, 89:477-479.
47. Neagoe P.E., Brkovic A., Hajjar F., Sirois M.G. Expression and release of angiopoietin-1 from human neutrophils: intracellular mechanisms. Growth Factors 2009, 27:335-344.
48. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997, 277:48-50.
49. Jones N., Iljin K., Dumont D.J., Alitalo K. Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol 2001, 2:257-267.
50. Dallabrida S.M., Ismail N.S., Pravda E.A., Parodi E.M., Dickie R., Durand E.M., et al. Integrin binding angiopoietin-1 monomers reduce cardiac hypertrophy. FASEB J 2008, 22:3010-3023.
51. Weber C.C., Cai H., Ehrbar M., Kubota H., Martiny-Baron G., Weber W., et al. Effects of protein and gene transfer of the angiopoietin-1 fibrinogen-like receptor-binding domain on endothelial and vessel organization. J Biol Chem 2005, 280:22445-22453.
52. Yacyshyn O.K., Lai P.F., Forse K., Teichert-Kuliszewska K., Jurasz P., Stewart D.J. Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in human endothelial cells. Angiogenesis 2009, 12:25-33.
53. Fiedler U., Reiss Y., Scharpfenecker M., Grunow V., Koidl S., Thurston G., et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006, 12:235-239.
54. Nilsson I., Shibuya M., Wennstrom S. Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res 2004, 299:476-485.
55. Holash J., Wiegand S.J., Yancopoulos G.D. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999, 18:5356-5362.
56. Pouyssegur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
57. Boussat S., Eddahibi S., Coste A., Fataccioli V., Gouge M., Housset B., et al. Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol 2000, 279:L371-L378.
58. Park J.H., Park K.J., Kim Y.S., Sheen S.S., Lee K.S., Lee H.N., et al. Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 2007, 132:200-206.
59. Jain R.K. Molecular regulation of vessel maturation. Nat Med 2003, 9:685-693.
60. Chen J.X., Zeng H., Reese J., Aschner J.L., Meyrick B. Overexpression of angiopoietin-2 impairs myocardial angiogenesis and exacerbates cardiac fibrosis in the diabetic db/db mouse model. Am J Physiol Heart Circ Physiol 2012 Feb 15, 302(4):H1003-H1012.
61. Fiedler U., Scharpfenecker M., Koidl S., Hegen A., Grunow V., Schmidt J.M., et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004, 103:4150-4156.
62. Mochizuki Y., Nakamura T., Kanetake H., Kanda S. Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn. J Cell Sci 2002, 115:175-183.
63. Teichert-Kuliszewska K., Maisonpierre P.C., Jones N., Campbell A.I., Master Z., Bendeck M.P., et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 2001, 49:659-670.
64. Daly C., Pasnikowski E., Burova E., Wong V., Aldrich T.H., Griffiths J., et al. Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci U S A 2006, 103:15491-15496.
65. Yuan H.T., Khankin E.V., Karumanchi S.A., Parikh S.M. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 2009, 29:2011-2022.
66. Lind A.J., Wikstrom P., Granfors T., Egevad L., Stattin P., Bergh A. Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate 2005, 62:394-399.
67. Brown L.F., Dezube B.J., Tognazzi K., Dvorak H.F., Yancopoulos G.D. Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 2000, 156:2179-2183.
68. Makinde T.O., Agrawal D.K. Increased expression of angiopoietins and Tie2 in the lungs of chronic asthmatic mice. Am J Respir Cell Mol Biol 2010, 44:384-393.
69. Valenzuela D.M., Griffiths J.A., Rojas J., Aldrich T.H., Jones P.F., Zhou H., et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci U S A 1999, 96:1904-1909.
70. Linares P.M., Gisbert J.P. Role of growth factors in the development of lymphangiogenesis driven by inflammatory bowel disease: a review. Inflamm Bowel Dis 2011, 17:1814-1821.
71. Saharinen P., Petrova T.V. Molecular regulation of lymphangiogenesis. Ann N Y Acad Sci 2004, 1014:76-87.
72. Yan Z.X., Jiang Z.H., Liu N.F. Angiopoietin-2 promotes inflammatory lymphangiogenesis and its effect can be blocked by the specific inhibitor L1-10. Am J Physiol Heart Circ Physiol 2011, 302:H215-H223.
73. Kajiya K., Kidoya H., Sawane M., Matsumoto-Okazaki Y., Yamanishi H., Furuse M., et al. Promotion of lymphatic integrity by angiopoietin-1/Tie2 signaling during inflammation. Am J Pathol 2011, 180(3):1273-1282.
74. Dellinger M., Hunter R., Bernas M., Gale N., Yancopoulos G., Erickson R., et al. Defective remodeling and maturation of the lymphatic vasculature in angiopoietin-2 deficient mice. Dev Biol 2008, 319:309-320.
75. Shimoda H., Bernas M.J., Witte M.H., Gale N.W., Yancopoulos G.D., Kato S. Abnormal recruitment of periendothelial cells to lymphatic capillaries in digestive organs of angiopoietin-2-deficient mice. Cell Tissue Res 2007, 328:329-337.
76. Cho C.H., Kammerer R.A., Lee H.J., Steinmetz M.O., Ryu Y.S., Lee S.H., et al. COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity. Proc Natl Acad Sci U S A 2004, 101:5547-5552.
77. Gale N.W., Thurston G., Davis S., Wiegand S.J., Holash J., Rudge J.S., et al. Complementary and coordinated roles of the VEGFs and angiopoietins during normal and pathologic vascular formation. Cold Spring Harb Symp Quant Biol 2002, 67:267-273.
78. Veikkola T., Alitalo K. Dual role of Ang2 in postnatal angiogenesis and lymphangiogenesis. Dev Cell 2002, 3:302-304.
79. Koutroubakis I.E., Xidakis C., Karmiris K., Sfiridaki A., Kandidaki E., Kouroumalis E.A. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease. Eur J Clin Invest 2006, 36:127-132.
80. Pousa I.D., Mate J., Salcedo-Mora X., Abreu M.T., Moreno-Otero R., Gisbert J.P. Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn's disease patients. Inflamm Bowel Dis 2008, 14:61-67.
81. Yoshizaki A., Nakayama T., Naito S., Sekine I. Expression patterns of angiopoietin-1, -2, and tie-2 receptor in ulcerative colitis support involvement of the angiopoietin/tie pathway in the progression of ulcerative colitis. Dig Dis Sci 2009, 54:2094-2099.
82. Linares P.M., Fernández-Contreras M.E., Algaba A., Guijarro Rojas M., Bermejo F., Chaparro M., et al. Immunohistochemical expression of angiopoietin 1 (Ang1) and microvessels density in colon of patients with inflammatory bowel disease (IBD). J Crohns Colitis 2012, 6:S21-S22.
83. Koutroubakis I.E., Xidakis C., Karmiris K., Sfiridaki A., Kandidaki E., Kouroumalis E.A. Serum angiogenin in inflammatory bowel disease. Dig Dis Sci 2004, 49:1758-1762.
84. Oikonomou K.A., Kapsoritakis A.N., Kapsoritaki A.I., Manolakis A.C., Tiaka E.K., Tsiopoulos F.D., et al. Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease. Inflamm Bowel Dis 2010, 17:963-970.
85. Martin J.W., Mousa S.S., Shaker O., Mousa S.A. The multiple faces of nicotine and its implications in tissue and wound repair. Exp Dermatol 2009, 18:497-505.
86. Wu W.K., Cho C.H. The pharmacological actions of nicotine on the gastrointestinal tract. J Pharmacol Sci 2004, 94:348-358.
87. Pousa I.D., Algaba A., Linares P.M., Sanz-Cameno P., Mate J., Moreno-Otero R., et al. Corticosteroids modulate angiogenic soluble factors in ulcerative colitis patients. Dig Dis Sci 2010, 56:871-879.
88. Algaba A., Linares P.M., Fernández-Contreras M.E., Figuerola A., Calvet X., Guerra I., et al. The effect of infliximab and adalimumab treatment on angiogenic factor levels in patients with inflammatory bowel disease (IBD). J Crohns Colitis 2012, 6:S27.
89. Algaba A., Linares P.M., Fernández-Contreras M.E., Ordoñez A., Trápaga J., Guerra I., et al. Relationship between histological activity of inflammatory bowel disease (IBD) and angiogenic and lymphangiogenic factors (ALF). J Crohns Colitis 2012, 6:S31.
90. Linares P.M., Algaba A., Fernández-Contreras M.E., Guerra I., Chaparro M., Rodríguez-Agulló J.L., et al. Relationship between levels of angiogenic and lymphangiogenic factors (ALF) and the extension, endoscopic activity, and acute phase reactants (APR) in patients with ulcerative colitis (UC). J Crohns Colitis 2012, 6:S30-S31.